Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size

A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study

This study has been completed.
Sponsor:
Collaborator:
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Seattle Genetics, Inc.
ClinicalTrials.gov Identifier:
NCT00947856
First received: July 24, 2009
Last updated: May 30, 2014
Last verified: May 2014
History of Changes
Results First Received: March 21, 2014  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Disease, Hodgkin
Lymphoma, Large-Cell, Anaplastic
Lymphoma, Non-Hodgkin
Intervention: Drug: brentuximab vedotin

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Jul 2009 - Mar 2013

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
BV Extension Brentuximab vedotin 1.2 or 1.8 mg/kg every 3 weeks by IV infusion (continued treatment)
BV Retreatment Brentuximab vedotin 1.2 or 1.8 mg/kg every 3 weeks by IV infusion (retreatment after relapse)

Participant Flow for 2 periods

 Period 1:   Treatment Period
    BV Extension     BV Retreatment  
STARTED     78     32 [1]
COMPLETED     0     0 [2]
NOT COMPLETED     78     32  
Progressive Disease                 33                 12  
Adverse Event                 15                 9  
Physician Decision                 14                 6  
Study Stopped by Sponsor                 4                 4  
Withdrawal by Subject                 12                 1  
[1] Two patients in extension arm re-enrolled in retreatment arm and are represented in both arms
[2] Patients treated until disease progression, unacceptable toxicity or study closure

Period 2:   Follow-up Period
    BV Extension     BV Retreatment  
STARTED     78     32 [1]
COMPLETED     27     9 [2]
NOT COMPLETED     51     23  
Study Stopped by Sponsor                 40                 20  
Re-enrolled for Retreatment                 0                 3  
Lost to Follow-up                 7                 0  
Other                 3                 0  
Withdrawal by Subject                 1                 0  
[1] All participants were to be followed after treatment
[2] Completed survival follow-up due to death



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
All participants who received treatment

Reporting Groups
  Description
BV Extension Brentuximab vedotin 1.2 or 1.8 mg/kg every 3 weeks by IV infusion (continued treatment)
BV Retreatment Brentuximab vedotin 1.2 or 1.8 mg/kg every 3 weeks by IV infusion (retreatment after relapse)
Total Total of all reporting groups

Baseline Measures
    BV Extension     BV Retreatment     Total  
Number of Participants  
[units: participants]
 		  78     32     110  
Age, Customized  
[units: years]
Median ( Full Range ) 		  32  
  ( 15 to 78 )   		  37  
  ( 16 to 72 )   		  33.5  
  ( 15 to 78 )  
Gender  
[units: participants]
 		     
Female     35     17     52  
Male     43     15     58  
Race (NIH/OMB)  
[units: participants]
 		     
American Indian or Alaska Native     0     0     0  
Asian     3     0     3  
Native Hawaiian or Other Pacific Islander     1     0     1  
Black or African American     7     4     11  
White     66     27     93  
More than one race     0     0     0  
Unknown or Not Reported     1     1     2  
Region of Enrollment  
[units: participants]
 		     
France     0     3     3  
United States     78     29     107  
Eastern Cooperative Oncology Group Performance Status [1]
[units: participants]
 		     
0     47     12     59  
1     30     18     48  
2     0     2     2  
3-5     0     0     0  
Missing     1     0     1  
Disease diagnosis  
[units: participants]
 		     
Hodgkin lymphoma (HL)     68     21     89  
Systemic anaplastic large cell lymphoma (ALCL)     8     8     16  
Other     2     3     5  
[1]

0 = Normal activity

  1. = Symptoms but ambulatory
  2. = In bed <50% of the time
  3. = In bed >50% of the time
  4. = 100% bedridden
  5. = Dead



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Objective Response Rate by Investigator   [ Time Frame: Up to approximately 38 months ]
  Show Outcome Measure 1

2.  Primary:   Adverse Events by Severity, Seriousness, and Relationship to Treatment   [ Time Frame: up to 39 months ]
  Show Outcome Measure 2

3.  Primary:   Laboratory Abnormalities >/= Grade 3   [ Time Frame: Up to 39 months ]
  Show Outcome Measure 3

4.  Secondary:   Duration of Objective Response by Kaplan-Meier Analysis   [ Time Frame: Up to 38 months ]
  Show Outcome Measure 4

5.  Secondary:   Progression-free Survival by Kaplan-Meier Analysis   [ Time Frame: Up to approximately 29 months ]
  Show Outcome Measure 5

6.  Secondary:   Overall Survival   [ Time Frame: Up to approximately 41 months ]
  Show Outcome Measure 6

7.  Secondary:   Incidence of Antitherapeutic Antibodies   [ Time Frame: Up to 39 months ]
  Show Outcome Measure 7


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Chief Medical Officer
Organization: Seattle Genetics, Inc.
phone: 855-473-2436
e-mail: medinfo@seagen.com


Publications of Results:

Publications automatically indexed to this study:


Responsible Party: Seattle Genetics, Inc.
ClinicalTrials.gov Identifier: NCT00947856     History of Changes
Other Study ID Numbers: SGN35-006, 2010-019932-11
Study First Received: July 24, 2009
Results First Received: March 21, 2014
Last Updated: May 30, 2014
Health Authority: United States: Food and Drug Administration